Home > News > Q10: Stuart Hendry, CEO at Sphere Medical
September 5th, 2007
Q10: Stuart Hendry, CEO at Sphere Medical
Abstract:
Sphere, which was founded in 2002, is combining its patented microtechnology and nanotechnology to develop unique dice-sized microanalysers capable of measuring several key compounds such as, glucose, blood gases and drugs, simultaneously at low cost. Mortality in critical care remains unacceptably high, with associated costs of £billions annually. Real time measurement of drugs and physiological parameters, facilitating tight control of therapy, has been shown to dramatically improve patient outcomes, saving lives and money. Unfortunately, cost effective products to achieve this ideal are not currently available.
Source:
businessweekly.co.uk
Bookmark:
| Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||